D-0876-2026 Class II Ongoing

Recalled by Par Health USA, LLC — Rochester, MI

FDA drug recall D-0876-2026 was initiated by Par Health USA, LLC on Sep 8, 2026 and is designated Class II. Reason for recall: Crystallization The recall status is ongoing. Affected quantity: 154210 bottles.

Recall details

Product Type
Drugs
Report Date
Oct 7, 2026
Initiation Date
Sep 8, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
154210 bottles

Product description

Buprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: Endo USA, Malvern, PA, NDC 42023-179-05

Reason for recall

Crystallization

Distribution pattern

U.S. Nationwide

Code information

Lot#:83912, Exp Date 10/2026 Lot#:84234, Exp Date 11/2026 Lot#:84990, Exp Date 11/2026 Lot#:85003, Exp Date 12/2026 Lot#:86443, Exp Date 01/2027 Lot#:89909, Exp Date 05/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0876-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0876-2026. Report a data issue: hello@regdatalab.com.